PRVB - Follow-up data published for Provention Bio's type 1 diabetes candidate teplizumab

Provention Bio (PRVB) says extended follow-up data from a phase 3 trial of its type 1 diabetes candidate teplizumab showed that a single 14-day infusion of the monoclonal antibody (mAb) delayed the onset of clinical disease and insulin dependence in at-risk type 1 diabetes (T1D) patients by approximately three years (median of 32.5 months)The additional data adds one year to previously reported results.The new data was published in the journal Science Translational Medicine.In January, Provention submitted a BLA to the FDA for the anti-CD3 mAb with a PDUFA date of July 2, 2021.Provention shares are up 2.4% to $12.02 in afterhours trading.

For further details see:

Follow-up data published for Provention Bio's type 1 diabetes candidate teplizumab